News

Swiss biotech company Asceneuron SA successfully closed a $100 mio oversubscribed Series C financing round. The financing round was led by Novo Holdings with new investment from EQT Life Sciences - LSP Dementia Fund, OrbiMed and SR One, alongside participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc.

The funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer’s disease.

BGPartner advised lead investor Novo Holdings as well as the investors EQT Life Sciences - LSP Dementia Fund, OrbiMed and SR One, on all Swiss legal matters and the negotiations of this Series C financing round. The team consisted of Oliver Gnehm (Partner), Victoria Marty (Senior Associate) and Tessa Douma (Associate).

More information can be found here.

More information about our legal and negotiation expertise can be found here.

After successfully advising Lalique Group SA (securities symbol: LLQ), which is listed on the SIX Swiss Exchange, on the organization of its Annual General Meeting and the adaptation of its Articles of Association to the new Swiss Stock Corporation Act last year, BGPartner was also able to support the company at this year's Annual General Meeting. The Annual General Meeting was held on June 29, 2024 at The Dolder Grand in Zurich and was attended by over 300 shareholders, who approved all of the proposals put forward by the Board of Directors. Among other things, the Annual General Meeting also voted on the delisting of the company's shares from the SIX Swiss Exchange.

The BGPartner team consisted of Dr. Alain P. Röthlisberger (Partner, Team Lead), Oliver Gnehm (Partner) and David Dalla Veccia (Senior Associate). BGPartner has proven expertise in the areas of corporate and commercial law (including corporate governance and capital markets law issues) as well as M&A and private equity and regularly advises national and international public companies, their boards of directors, investors and shareholders as well as entrepreneurs from all industries.

The annual Jazz Brunch is as much a part of BGPartner as the negotiation competence or the different legal services. For the 24rd time over 240 guests enjoyed culinary delights, fantastic jazz music, great weather and a relaxed atmosphere on the Gurten Hill (Berne).

A big thank you to the Gurten - Park im Grünen crew under the leadership of Patrick Vogel for the smooth running of the event and the Imelda Gabs Jazz band, who has remained loyal to us over the years, despite her rising fame. Here you can find the photo gallery. 

BGPartner advised Memo Therapeutics Ltd, a late-stage biotech company developing a best-in-class BKV-neutralizing antibody for BKV infection in kidney transplantation, on the successful completion of its Series C extension financing. Memo Therapeutics Ltd raised a further CHF 20 million, bringing the total amount raised in this funding round to CHF 45 million. The Series C extension financing was led by Ysios Capital and Kurma Partners and was joined by existing investors.

The new funding will be used to bolster the clinical advancement of Memo Therapeutic’s lead asset, AntiBKV. There are more than 100,000 kidney transplants worldwide each year and 20,000 of these are at risk from developing BK virus associated nephropathy. With no disease modifying therapies available, there is an urgent need for a treatment. FDA fast track status has already been obtained.

BGPartner assisted Memo Therapeutics Ltd in all legal and negotiation matters in this transaction and is proud to have been advising Memo Therapeutics Ltd for several years already. The team was led by Oliver Gnehm (Partner) and consisted of Victoria Marty (Senior Associate) and Barbara Meise (Associate).

Click here for the complete media release.

More information about our legal and negotiation expertise can be found here.

International sporting history was made with the breathtaking performance of the Kiwi Fondue Team in July 2023. The Kiwi Fondue Team broke the world record in the Pacific race World's Toughest Row.

Dr. Alain P. Röthlisberger and navigator Alexander Gammeter analyzed the race together in the second interview and compared the parallels between challenging negotiations and extreme sports.

Find out what else makes the Kiwi Fondue Team so successful in the detailed interview on YouTube.

Are you interested in the topic of negotiating? Then continue here.